Glucan Matrix
Glucan Matrix - Related Videos
02:25
An Assay for Analyzing Test β-Glucan as an Immunotherapy Strategy against Brain Cancer Cells
0 Views •
2025
This video demonstrates an in vitro assay utilizing β-glucans to activate microglial cells for the production of superoxide radicals, a reactive oxygen species. In brain cancer cells, the generated reactive oxidants actively suppress tumor cell proliferation and induce cell death.
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
0 Views •
Cited by 1 •
2023
The present protocol describes the purification steps and subsequent studies of four different fungal β-glucans as potential immunomodulatory molecules that enhance the anti-tumoral properties of microglia against glioblastoma cells.
06:13
Determination of Glucan Chain Length Distribution of Glycogen Using the Fluorophore-Assisted Carbohydrate Electrophoresis (FACE) Method
0 Views •
Cited by 4 •
2022
In the present protocol, the Fluorophore-Assisted Carbohydrate Electrophoresis (FACE) technique is used to determine the chain length distribution (CLD) and the average chain length (ACL) of glycogen.
01:18
The Bone Matrix
0 Views •
2025
Bone contains a relatively small number of cells entrenched in a matrix of collagen fibers that provide an adherent surface for inorganic salt crystals. Both components of the matrix, organic and inorganic, contribute to the unusual properties of bone. Without collagen, bones would be brittle and shatter easily. Without mineral crystals, bones would flex and provide little support. This can be observed by an experiment: when the minerals of a bone are dissolved by soaking the bone in acid or...
01:42
The Extracellular Matrix
0 Views •
2026
In order to maintain tissue organization, many animal cells are surrounded by structural molecules that make up the extracellular matrix (ECM). Together, the molecules in the ECM maintain the structural integrity of tissue as well as the remarkable specific properties of certain tissues.Composition of the Extracellular MatrixThe extracellular matrix (ECM) is commonly composed of ground substance, a gel-like fluid, fibrous components, and many structurally and functionally diverse molecules.
FAQs
Reduced drug access is a central consequence of the glucan matrix in fungal biofilms. Its hydrated scaffold can restrict antimicrobial penetration, so an antifungal may encounter lower effective access to target cells than it would in a free-living population. This helps explain why biofilm-associated infections can respond poorly even when free-living cells appear drug susceptible.
Matrix composition and organization influence how effectively the scaffold protects microbial communities. β-1,3-glucan and related carbohydrates can create a structured environment that both limits penetration and binds or sequesters antifungal drugs. Consequently, changes in the matrix may alter the amount of drug reaching target cells and help determine treatment response in pathogenic fungal biofilms.
Free-living cell susceptibility does not necessarily predict the response of a biofilm-associated infection. Cells within a biofilm remain surrounded by the matrix, which can reduce drug access before the antifungal reaches its cellular target. Pharmacological studies therefore need to consider the protected community environment when interpreting why conventional treatment performs poorly.
Three complementary strategies are supported by matrix-focused pharmacology: inhibit glucan production, degrade the existing scaffold, or improve antifungal delivery through it. The first two aim to reduce the barrier or its formation, whereas the third seeks to increase drug access to target cells. These approaches may address protection that conventional antifungals alone cannot overcome.
Researchers should examine matrix composition and organization alongside antifungal access and treatment response. Identifying the carbohydrate components that form the scaffold can reveal whether protection results primarily from restricted penetration, drug binding or sequestration, or both. This information helps connect biofilm structure with pharmacological outcomes and supports selection of a suitable intervention strategy.
The matrix provides a pharmacological explanation for treatment failure that is not apparent from free-living cell susceptibility alone. By studying how it protects fungal communities and alters antifungal access, researchers can design interventions that weaken glucan formation, remove the scaffold, or deliver drugs more effectively. These efforts directly support improved treatment strategies for biofilm-associated infections.